AI Tools Can Predict Left Ventricular Dysfunction in Women of Reproductive Age
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 14, 2025 -- Artificial intelligence (AI) tools are effective for detecting left ventricular systolic dysfunction (LVSD) among women of reproductive age seen in primary care, according to a study published online in the March/April issue of the Annals of Family Medicine.
Anja Kinaszczuk, D.O., from the Mayo Clinic in Jacksonville, Florida, and colleagues enrolled 100 women aged 18 to 49 years who had a primary care physician and a scheduled echocardiography at Mayo Clinic Florida (cohort 1) in a pilot cross-sectional study. On the date of echocardiography, 12-lead electrocardiography (ECG) and digital stethoscope recordings were performed. Probabilities for LVSD, defined as left ventricular ejection fraction <50 percent, were generated using deep learning for the 12-lead ECG and stethoscope (AI-ECG and AI-stethoscope) recordings. The prevalence of positive AI screening results when deployed for routine use was estimated in a second cohort of 100 participants seen in primary care (cohort 2).
In cohort 1, 5 percent had LVSD. The researchers found that the area under the curve was 0.94 and 0.98 for AI-ECG and AI-stethoscope (maximum prediction across all chest locations), respectively, for predicting LVSD. The prevalence of a positive AI screen was 1 percent for AI-ECG and 3.2 percent for AI-stethoscope in cohort 2.
"The use of AI-ECG and the AI-stethoscope appear to be effective in screening for LVSD among women of reproductive potential in a primary care clinic setting. These tools offer a rapid and cost-effective solution for preconception cardiovascular screening," the authors write.
The Mayo Clinic has licensed the 12-lead electrocardiography technology to Eko Devices and to Anumana and may derive financial benefit from use of this technology.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Socioeconomic Status Tied to New Diagnosis of Hidradenitis Suppurativa
WEDNESDAY, May 14, 2025 -- For dermatology patients, neighborhood-level socioeconomic status (nSES) is associated with a new diagnosis of hidradenitis suppurativa (HS), according...
Molecular Monitoring Improves Survival in Some Patients With Newly Diagnosed Leukemia
WEDNESDAY, May 14, 2025 -- Molecular monitoring of measurable residual disease (MRD), coupled with guided treatment, contributes to improved survival for patients with newly...
Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma
WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.